Knockout of AKAP150 improves impaired BK channel-mediated vascular dysfunction through the Akt/GSK3β signalling pathway in diabetes mellitus

J Cell Mol Med. 2020 Apr;24(8):4716-4725. doi: 10.1111/jcmm.15143. Epub 2020 Mar 12.

Abstract

Vascular dysfunction resulting from diabetes is an important factor in arteriosclerosis. Previous studies have shown that during hyperglycaemia and diabetes, AKAP150 promotes vascular tone enhancement by intensifying the remodelling of the BK channel. However, the interaction between AKAP150 and the BK channel remains open to discussion. In this study, we investigated the regulation of impaired BK channel-mediated vascular dysfunction in diabetes mellitus. Using AKAP150 null mice (AKAP150-/- ) and wild-type (WT) control mice (C57BL/6J), diabetes was induced by intraperitoneal injection of streptozotocin. We found that knockout of AKAP150 reversed vascular remodelling and fibrosis in mice with diabetes and in AKAP150-/- diabetic mice. Impaired Akt/GSK3β signalling contributed to decreased BK-β1 expression in aortas from diabetic mice, and the silencing of AKAP150 increased Akt phosphorylation and BK-β1 expression in MOVAS cells treated with HG medium. The inhibition of Akt activity caused a decrease in BK-β1 expression, and treatment with AKAP150 siRNA suppressed GSK3β expression in the nuclei of MOVAS cells treated with HG. Knockout of AKAP150 reverses impaired BK channel-mediated vascular dysfunction through the Akt/GSK3β signalling pathway in diabetes mellitus.

Keywords: A-kinase anchoring protein; diabetes mellitus; the large-conductance Ca2+-activated K+ channel; vascular diseases; vascular smooth muscle cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • A Kinase Anchor Proteins / genetics*
  • Animals
  • Arteriosclerosis / complications
  • Arteriosclerosis / genetics
  • Arteriosclerosis / pathology
  • Arteriosclerosis / therapy
  • Diabetes Complications / genetics*
  • Diabetes Complications / pathology
  • Diabetes Complications / therapy
  • Diabetes Mellitus, Experimental / genetics*
  • Diabetes Mellitus, Experimental / pathology
  • Diabetes Mellitus, Experimental / therapy
  • Disease Models, Animal
  • Glycogen Synthase Kinase 3 beta / antagonists & inhibitors
  • Glycogen Synthase Kinase 3 beta / genetics*
  • Humans
  • Hyperglycemia / complications
  • Hyperglycemia / genetics
  • Hyperglycemia / pathology
  • Hyperglycemia / therapy
  • Large-Conductance Calcium-Activated Potassium Channel beta Subunits / genetics*
  • Large-Conductance Calcium-Activated Potassium Channels / genetics
  • Mice
  • Mice, Knockout
  • RNA, Small Interfering / genetics
  • RNA, Small Interfering / pharmacology

Substances

  • A Kinase Anchor Proteins
  • Akap5 protein, mouse
  • Kcnmb1 protein, mouse
  • Large-Conductance Calcium-Activated Potassium Channel beta Subunits
  • Large-Conductance Calcium-Activated Potassium Channels
  • RNA, Small Interfering
  • Glycogen Synthase Kinase 3 beta
  • Gsk3b protein, mouse